基因风险评分联合临床变量预测早期类风湿关节炎肺纤维化的验证
本研究在瑞典北部1996至2016年诊断的1118例早期RA起始队列中外部验证VARA-ILD-GRS和VARA-ILD-CRS对RA相关肺纤维化的预测效能。1115例完整数据中60例(5.6%)诊断PF;GRS与RA-PF显著相关(OR 2.6,95%CI 1.6-4.5),CRS的AUC 0.75优于GRS单独AUC 0.62。结论支持遗传与临床数据整合用于RA-ILD风险分层。
要点
- GRS与RA-PF显著相关,OR 2.6(95%CI 1.6-4.5)。
- CRS的AUC 0.75,优于GRS单独AUC 0.62(P<0.001)。
- PF与年龄、RF阳性、疾病活动度及MUC5B、FAM13A SNP相关。
核心结论
- 本研究外部验证了VARA-ILD-GRS和VARA-ILD-CRS在RA队列中的泛化性和识别RA-ILD高危个体的有效性。
研究设计与样本
- 研究使用瑞典北部1996至2016年诊断的1118例RA起始队列,系统性收集临床数据并对12个与特发性PF相关的SNP进行基因分型。
- 采用逻辑回归和AUC评估GRS及联合临床数据的CRS预测RA-PF的性能。
主要发现
- 1115例完整数据中60例(5.6%)诊断PF。
- PF与年龄、类风湿因子阳性、疾病活动度及MUC5B(rs35705950)和FAM13A(rs2609255)SNP显著相关。
- GRS与RA-PF显著相关(OR 2.6,95%CI 1.6-4.5)。
- CRS的AUC 0.75(P<0.001)优于GRS单独的AUC 0.62。
关键数值与推荐
- GRS与RA-PF的OR 2.6(95%CI 1.6-4.5)。
- CRS预测RA-PF的AUC 0.75(P<0.001),GRS单独AUC 0.62。
临床怎么用
- 研究结果表明CRS在区分RA-PF方面优于GRS,提示其临床实践中具有潜在应用价值。
- 研究结果支持将遗传和临床数据整合到风险分层模型中,可能显著改善对有RA-PF风险患者的筛查策略。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Pulmonary fibrosis (PF) is a severe extra-articular manifestation of rheumatoid arthritis (RA). This study aimed to externally validate a genetic risk score (GRS) and a combined risk score (CRS) for predicting the risk of RA-associated PF in an independent cohort of patients with early RA. METHODS: This study used an inception cohort of 1,118 patients diagnosed with RA from northern Sweden between 1996 and 2016. Clinical data were systematically collected, and genotyping was performed for 12 single-nucleotide polymorphisms (SNPs) associated with idiopathic PF. Statistical analyses, including logistic regression and area under the curve (AUC) assessments, were conducted to evaluate the performance of the GRS and in combination with clinical data as the CRS in predicting RA-PF development. RESULTS: Of the 1,115 patients with complete data, 60 (5.6%) were diagnosed with PF. PF was significantly associated with age, rheumatoid factor positivity, disease activity, and MUC5B (rs35705950) and FAM13A(rs2609255) SNPs. The GRS demonstrated a significant association with RA-PF (odds ratio 2.6, 95% confidence interval 1.6-4.5), whereas the CRS exhibited superior performance (AUC 0.75, P < 0.001) compared to the GRS alone (AUC 0.62). The combined risk score outperformed the GRS in discriminating RA-PF, indicating its potential utility in clinical practice. CONCLUSION: This study provides external validation of the Veterans Affairs Rheumatoid Arthritis Registry interstitial lung disease GRS (VARA-ILD-GRS) and the VARA-ILD-CRS in an RA cohort, demonstrating their generalizability and effectiveness in identifying individuals at high risk for RA-ILD. The findings support the integration of genetic and clinical data in risk stratification models, which could significantly improve screening strategies for patients with RA at risk of developing PF.
引用
- Brink M, Wheeler A, England BR, et al. Validation of a Genetic Risk Score Combined With Clinical Variables for Predicting Pulmonary Fibrosis in Early Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2026. PMID: 41236136. doi:10.1002/acr.25696
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。